Orgenesis Inc. Stock price

Equities

ORGS

US68619K2042

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
0.822 USD -3.29% Intraday chart for Orgenesis Inc. -5.52% +64.17%
Sales 2021 35.5M Sales 2022 36.02M Capitalization 49.81M
Net income 2021 -18M Net income 2022 -14M EV / Sales 2021 2.15 x
Net Debt 2021 6.37M Net Debt 2022 14.96M EV / Sales 2022 1.8 x
P/E ratio 2021
-3.87 x
P/E ratio 2022
-3.29 x
Employees 167
Yield 2021 *
-
Yield 2022
-
Free-Float 78.41%
More Fundamentals * Assessed data
Dynamic Chart
1 day-3.29%
1 week-5.52%
Current month+28.40%
1 month+31.94%
3 months+63.75%
6 months+32.58%
Current year+64.17%
More quotes
1 week
0.82
Extreme 0.8216
0.91
1 month
0.65
Extreme 0.6454
0.91
Current year
0.25
Extreme 0.25
0.91
1 year
0.25
Extreme 0.25
1.50
3 years
0.25
Extreme 0.25
6.47
5 years
0.25
Extreme 0.25
8.30
10 years
0.25
Extreme 0.25
16.80
More quotes
Managers TitleAgeSince
Founder 70 08-06-04
Chief Executive Officer 55 12-02-01
Director of Finance/CFO 54 Jan. 01
Members of the board TitleAgeSince
Director/Board Member 64 13-07-17
Chief Executive Officer 55 12-02-01
Director/Board Member 54 20-01-08
More insiders
Date Price Change Volume
24-03-28 0.822 -3.29% 11,222
24-03-27 0.85 -0.13% 15,433
24-03-26 0.8511 -5.33% 20,616
24-03-25 0.899 0.00% 50,473
24-03-22 0.899 +3.33% 32,887

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
  1. Stock
  2. Equities
  3. Stock Orgenesis Inc. - Nasdaq